Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
University of Washington
ClinicalTrials.gov Identifier:
NCT01720602
First received: October 31, 2012
Last updated: November 5, 2014
Last verified: November 2014
Results First Received: October 30, 2014  
Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Male Breast Cancer
Recurrent Breast Cancer
Stage IV Breast Cancer
Interventions: Drug: vorinostat
Drug: anastrozole
Drug: letrozole
Drug: exemestane
Procedure: positron emission tomography
Radiation: F-18 16 alpha-fluoroestradiol
Radiation: fludeoxyglucose F 18
Other: laboratory biomarker analysis

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Treatment (Vorinostat, AI Therapy)

Patients receive vorinostat PO 5 days a week for 3 weeks. Patients also receive AI therapy comprising either anastrozole PO daily, letrozole PO daily, or exemestane PO daily for 4 weeks. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity.

vorinostat: Given PO

anastrozole: Given PO

letrozole: Given PO

exemestane: Given PO

positron emission tomography: Correlative studies

F-18 16 alpha-fluoroestradiol: Correlative studies

fludeoxyglucose F 18: Correlative studies

laboratory biomarker analysis: Correlative studies


Participant Flow:   Overall Study
    Treatment (Vorinostat, AI Therapy)  
STARTED     15  
COMPLETED     10  
NOT COMPLETED     5  
Adverse Event                 3  
Progressive disease on therapy                 2  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Treatment (Vorinostat, AI Therapy)

Patients receive vorinostat PO 5 days a week for 3 weeks. Patients also receive AI therapy comprising either anastrozole PO daily, letrozole PO daily, or exemestane PO daily for 4 weeks. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity.

vorinostat: Given PO

anastrozole: Given PO

letrozole: Given PO

exemestane: Given PO

positron emission tomography: Correlative studies

F-18 16 alpha-fluoroestradiol: Correlative studies

fludeoxyglucose F 18: Correlative studies

laboratory biomarker analysis: Correlative studies


Baseline Measures
    Treatment (Vorinostat, AI Therapy)  
Number of Participants  
[units: participants]
  15  
Age  
[units: participants]
 
<=18 years     0  
Between 18 and 65 years     7  
>=65 years     8  
Gender  
[units: participants]
 
Female     15  
Male     0  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Rate of Clinical Benefit of Patients Receiving Vorinostat/AI Combination Therapy According to RECIST   [ Time Frame: 8 weeks ]

2.  Primary:   Response Rate According to RECIST   [ Time Frame: 8 weeks ]

3.  Secondary:   Duration of Response   [ Time Frame: Up to 5 years ]

4.  Secondary:   Progression-free Survival (PFS)   [ Time Frame: Up to 5 years ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   No

5.  Secondary:   Overall Survival   [ Time Frame: Up to 5 years ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   No


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Hannah Linden, MD
Organization: University of Washington
phone: 206-288-6989
e-mail: hmlinden@u.washington.edu


No publications provided


Responsible Party: University of Washington
ClinicalTrials.gov Identifier: NCT01720602     History of Changes
Other Study ID Numbers: 7841, NCI-2012-02004, P30CA015704
Study First Received: October 31, 2012
Results First Received: October 30, 2014
Last Updated: November 5, 2014
Health Authority: United States: Food and Drug Administration